164 related articles for article (PubMed ID: 21818111)
1. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
Metzgeroth G; Erben P; Martin H; Mousset S; Teichmann M; Walz C; Klippstein T; Hochhaus A; Cross NC; Hofmann WK; Reiter A
Leukemia; 2012 Jan; 26(1):162-4. PubMed ID: 21818111
[No Abstract] [Full Text] [Related]
2. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
[TBL] [Abstract][Full Text] [Related]
3. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia.
Al-Riyami AZ; Hudoba M; Young S; Forrest D
Leuk Lymphoma; 2013 Aug; 54(8):1788-90. PubMed ID: 23157309
[No Abstract] [Full Text] [Related]
5. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
[TBL] [Abstract][Full Text] [Related]
6. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
7. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
8. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].
Qu SQ; Wang Y; Sun XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):159-61. PubMed ID: 23611226
[No Abstract] [Full Text] [Related]
9. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).
von Bubnoff N; Gorantla SP; Thöne S; Peschel C; Duyster J
Blood; 2006 Jun; 107(12):4970-1; author reply 4972. PubMed ID: 16754777
[No Abstract] [Full Text] [Related]
10. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J
Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
[TBL] [Abstract][Full Text] [Related]
11. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
Pitini V; Sturniolo G; Cavallari V; Arrigo C
Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
[No Abstract] [Full Text] [Related]
12. An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report.
Papanikolaou X; Kotsopoulou M; Triantafillopoulou ID; Zoi A; Chatziantoniou V; Maltezas D; Mitsouli-Mentzikof C
Ann Hematol; 2012 May; 91(5):785-787. PubMed ID: 21881824
[No Abstract] [Full Text] [Related]
13. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
14. Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.
Burbury K; Chew LP; Westerman D; Catalano A; Seymour JF
Leuk Lymphoma; 2011 Feb; 52(2):335-8. PubMed ID: 21281241
[No Abstract] [Full Text] [Related]
15. Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib.
Hus M; Helbig G; Cioch M; Szczepanska-Szerej H; Wieczorek P; Woźniak M; Kozinska J; Morawska M; Dmoszynska A; Kyrcz-Krzemien S; Kata D
Leuk Res; 2011 Mar; 35(3):e15-7. PubMed ID: 21093052
[No Abstract] [Full Text] [Related]
16. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
von Bubnoff N; Gorantla SP; Engh RA; Oliveira TM; Thöne S; Aberg E; Peschel C; Duyster J
Oncogene; 2011 Feb; 30(8):933-43. PubMed ID: 20972453
[TBL] [Abstract][Full Text] [Related]
17. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up.
Helbig G; Moskwa A; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Zdziarska B; Brzeźniakiewicz K; Pogrzeba J; Krzemień S
Br J Haematol; 2009 Apr; 145(1):132-4. PubMed ID: 19120352
[No Abstract] [Full Text] [Related]
18. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
[TBL] [Abstract][Full Text] [Related]
19. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
20. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
Tanaka H; Iwato K; Asou H; Kimura A
Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
